Ads
related to: multiple myeloma bone marrow treatment for hair loss- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
consumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
If there are no symptoms, but a paraprotein typical of myeloma and diagnostic bone marrow is present without end-organ damage, treatment is usually deferred or restricted to clinical trials. [105] Treatment for multiple myeloma is focused on decreasing the clonal plasma cell population and consequently decrease the symptoms of disease.
This treatment method is commonly linked with blood cancers like multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It is also used in solid tumors such as germ cell tumors and certain high risk or recurrent breast cancers. Multiple myeloma, a type of plasma cell cancer [3] is an indication for HDC. Typically it follows stem cell ...
Cyclophosphamide (CP), also known as cytophosphane among other names, [3] is a medication used as chemotherapy and to suppress the immune system. [4] As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. [4]
Elevated levels of DKK1 in bone marrow, plasma and peripheral blood are associated with the presence of osteolytic bone lesions in patients with multiple myeloma. [5] Due to the role of DKK1 in inflammation induced bone loss DKK1 is under investigation as target for therapeutic strategies in medicine and dentistry. [12] [13] [14]
Bone marrow suppression, including Decreased white blood cell count causing increased risk of infection; Decreased platelet count causing increased risk of bleeding; Less common side effects include: Severe allergic reactions [7] Pulmonary fibrosis (scarring of lung tissue) including fatal outcomes (usually only with prolonged use) Hair loss
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density. An osteolytic lesion (from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including breast cancer and multiple myeloma.